Marie Claire Recognizes ZORYVE for Atopic Dermatitis Treatment
Key Takeaways
- ZORYVE (roflumilast) cream 0.15% received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, according to an announcement from Arcutis.
- The prescription, nonsteroidal topical therapy is indicated for mild to moderate atopic dermatitis in adults and pediatric patients aged 6 years and older.
- The recognition adds to previous beauty-industry awards for ZORYVE products from Allure and Glamour.
Arcutis Biotherapeutics announced that roflumilast cream 0.15% (ZORYVE) received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, a new category recognizing innovation in prescription dermatologic treatments.
The award recognizes ZORYVE for its use in atopic dermatitis, a chronic inflammatory skin disease commonly characterized by pruritus and eczematous lesions. According to the press release, Marie Claire created the prescription skin solution category to recognize medical innovation in skin care, making ZORYVE the first medication to receive the distinction. The recognition is the third major beauty-industry award cited by Arcutis for the ZORYVE franchise. Allure named ZORYVE cream 0.15%, ZORYVE cream 0.3%, and ZORYVE topical foam 0.3% recipients of its 2025 Best of Beauty Breakthrough Award. Glamour previously recognized ZORYVE cream 0.15% as its 2024 Best Eczema Product.
“The launch of Marie Claire’s Best Prescription Skin Solution Award recognizes something important: innovation in skincare doesn’t stop at the beauty counter. Prescription therapies can fundamentally change the experience of living with a chronic inflammatory skin disease, and that impact should not be understated,” said Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale School of Medicine, and Associate Director of Clinical Trials at CCD Research, in the press release. “As the inaugural recipient, ZORYVE exemplifies the kind of innovation this new category was created to recognize. ZORYVE is a non-steroidal treatment option that helps individuals with eczema achieve clearer skin and itch relief, with a formulation designed with the skin barrier in mind and without ingredients known to compromise it. That matters, because in eczema, restoring and protecting the skin barrier isn’t secondary to treatment — it’s central to it.”
Source
Arcutis press release. October 6, 2026.